CDMOs these days need to be experienced and listen to the needs of the client, particularly in the development of not just antibody-drug conjugates, but bioconjugation and differentiated modalities that are then attached to the drug conjugates.
Time to clinic is vital for clients of CDMOs these days, as funding imperatives demand results to a timescale. Dishman Carbogen Amcis has streamlined services and collaborates with clients more closely than ever to support these shortened timelines, so clients can meet their goal.
Pharma Press Global and Drug Discovery and Development sat down with the Chief Commercial Officer of Dishman Carbogen Amcis, Angela Ameriks to talk about the requirements in 2026 of a modern CDMO.
Watch this exclusive Innovator’s Insight for the full picture.
